INmune Bio Receives R&D Rebates of Approximately $4.6 Million
INmune Bio received approximately $4.6 million in non-dilutive R&D cash rebates, comprising $4.2 million from Australia and $0.4 million from the United Kingdom. These proceeds exceeded the company's second-quarter operating cash burn, strengthening its balance sheet and extending its cash runway as it advances CORDStrom toward regulatory filings.
Key figures
- Uk rebate
- $0.4 million
- Total rebate
- $4.6 million
- Australia rebate
- $4.2 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.